Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Ovid Therapeutics Analyst Ratings and Price Targets | NASDAQ:OVID | Benzinga
Ovid Therapeutics Inc has a consensus price target of $3.71 based on the ratings of 8 analysts. The high is $7 issued by Ladenburg Thalmann on May 2, 2023. The low is $1.2 issued by Citigroup on June 18, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., BTIG, and Wedbush on May 27, 2025, March 24, 2025, and March 12, 2025, respectively. With an average price target of $2.83 between HC Wainwright & Co., BTIG, and Wedbush, there's an implied 771.53% upside for Ovid Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
BTIG
Wedbush
Oppenheimer
B. Riley Securities
1calculated from analyst ratings
Analyst Ratings for Ovid Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/27/2025 | Buy Now | 361.4% | HC Wainwright & Co. | Raghuram Selvaraju44% | $2 → $1.5 | Maintains | Buy | Get Alert |
| 03/24/2025 | Buy Now | 1130.39% | BTIG | Thomas Shrader40% | $5 → $4 | Maintains | Buy | Get Alert |
| 03/12/2025 | Buy Now | 822.79% | Wedbush | Laura Chico51% | $4 → $3 | Maintains | Outperform | Get Alert |
| 01/29/2025 | Buy Now | 1130.39% | Oppenheimer | Francois Brisebois40% | → $4 | Upgrade | Perform → Outperform | Get Alert |
| 12/04/2024 | Buy Now | 822.79% | HC Wainwright & Co. | Raghuram Selvaraju44% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 09/30/2024 | Buy Now | 822.79% | HC Wainwright & Co. | Raghuram Selvaraju44% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 08/19/2024 | Buy Now | 822.79% | HC Wainwright & Co. | Raghuram Selvaraju44% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2024 | Buy Now | 822.79% | HC Wainwright & Co. | Raghuram Selvaraju44% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 07/02/2024 | Buy Now | 822.79% | HC Wainwright & Co. | Raghuram Selvaraju44% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 06/18/2024 | Buy Now | 1437.99% | BTIG | Thomas Shrader40% | $11 → $5 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 822.79% | B. Riley Securities | Kalpit Patel41% | $9 → $3 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 269.12% | Citigroup | Yigal Nochomovitz54% | $3.5 → $1.2 | Maintains | Neutral | Get Alert |
| 06/18/2024 | Buy Now | 822.79% | HC Wainwright & Co. | Raghuram Selvaraju44% | $9 → $3 | Maintains | Buy | Get Alert |
| 05/16/2024 | Buy Now | 2668.38% | HC Wainwright & Co. | Raghuram Selvaraju44% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 976.59% | Citigroup | Yigal Nochomovitz54% | $4 → $3.5 | Maintains | Neutral | Get Alert |
| 04/30/2024 | Buy Now | 2668.38% | B. Riley Securities | Kalpit Patel41% | → $9 | Initiates | → Buy | Get Alert |
| 04/29/2024 | Buy Now | 2668.38% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $9 | Initiates | → Buy | Get Alert |
| 04/05/2024 | Buy Now | 2360.78% | Wedbush | Laura Chico51% | → $8 | Initiates | → Outperform | Get Alert |
| 12/21/2023 | Buy Now | 3283.57% | BTIG | Thomas Shrader40% | → $11 | Initiates | → Buy | Get Alert |
| 06/14/2023 | Buy Now | 1745.59% | JonesTrading | Sean Kim28% | → $6 | Initiates | → Buy | Get Alert |
| 05/02/2023 | Buy Now | 2053.18% | Ladenburg Thalmann | Michael Higgins45% | → $7 | Reiterates | → Buy | Get Alert |
| 08/29/2022 | Buy Now | 668.99% | Citigroup | Yigal Nochomovitz54% | $2.4 → $2.5 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Ovid Therapeutics (OVID) stock?
The latest price target for Ovid Therapeutics (NASDAQ:OVID) was reported by HC Wainwright & Co. on May 27, 2025. The analyst firm set a price target for $1.50 expecting OVID to rise to within 12 months (a possible 361.40% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ovid Therapeutics (OVID)?
The latest analyst rating for Ovid Therapeutics (NASDAQ:OVID) was provided by HC Wainwright & Co., and Ovid Therapeutics maintained their buy rating.
When was the last upgrade for Ovid Therapeutics (OVID)?
The last upgrade for Ovid Therapeutics Inc happened on January 29, 2025 when Oppenheimer raised their price target to $4. Oppenheimer previously had a perform for Ovid Therapeutics Inc.
When was the last downgrade for Ovid Therapeutics (OVID)?
There is no last downgrade for Ovid Therapeutics.
When is the next analyst rating going to be posted or updated for Ovid Therapeutics (OVID)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ovid Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ovid Therapeutics was filed on May 27, 2025 so you should expect the next rating to be made available sometime around May 27, 2026.
Is the Analyst Rating Ovid Therapeutics (OVID) correct?
While ratings are subjective and will change, the latest Ovid Therapeutics (OVID) rating was a maintained with a price target of $2.00 to $1.50. The current price Ovid Therapeutics (OVID) is trading at is $0.33, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
